Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

[1]Siegel RL, Miller KD, Jemal A. CA Cancer J Clin. 2017; 67:7–30.SiegelRLMillerKDJemalACA Cancer J Clin20176773010.3322/caac.2138728055103Search in Google Scholar

[2]Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG; Cyclins and Cell Cycle Control in Cancer and Disease Genes Cancer. 2012; 3:649–57.CasimiroMCCrosariolMLoroELiZPestellRGCyclins and Cell Cycle Control in Cancer and Disease Genes Cancer201236495710.1177/1947601913479022363674923634253Search in Google Scholar

[3]Zhu XL, Wang Z, Lei WB, Zhuang H, Hou W, Wen Y et al. Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research 2012; 31:94.ZhuXLWangZLeiWBZhuangHHouWWenYTumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinomaJournal of Experimental & Clinical Cancer Research2012319410.1186/1756-9966-31-94354199223151319Search in Google Scholar

[4]Hameed O and Humphrey PA. Immunohistochemistry in the diagnosis of minimal prostate cancer Current Diagnostic Pathology 2006; 12: 279–291.HameedOHumphreyPAImmunohistochemistry in the diagnosis of minimal prostate cancerCurrent Diagnostic Pathology20061227929110.1016/j.cdip.2006.05.003Search in Google Scholar

[5]Omar H, Jack S and Peter H. Immunohistochemical Stains for p63 and α-Methylacyl-CoA Racemase, Versus a Cocktail Comprising Both, in the Diagnosis of Prostatic Carcinoma: A Comparison of the Immunohistochemical Staining of 430 Foci in Radical Prostatectomy and Needle Biopsy Tissues. American Journal of Surgical Pathology 2005; 29 (5): 579–587.OmarHJackSPeterHImmunohistochemical Stains for p63 and α-Methylacyl-CoA Racemase, Versus a Cocktail Comprising Both, in the Diagnosis of Prostatic Carcinoma: A Comparison of the Immunohistochemical Staining of 430 Foci in Radical Prostatectomy and Needle Biopsy TissuesAmerican Journal of Surgical Pathology200529557958710.1097/01.pas.0000157936.93999.1815832080Search in Google Scholar

[6]Atta IS, Eid AG, El-Hag MA, AlQahtani FF. Can cyclin D1 be utilized as a second step “after basal cell marker” for both diagnosis and prognosis of prostatic adenocarcinoma? International Journal of Medical Science and Public Health 2016; 5(09).AttaISEidAGEl-HagMAAlQahtaniFFCan cyclin D1 be utilized as a second step “after basal cell marker” for both diagnosis and prognosis of prostatic adenocarcinoma?International Journal of Medical Science and Public Health201650910.5455/ijmsph.2016.28122015311Search in Google Scholar

[7]Gupta V, Garg M, Chaudhry M, Singh S, Sen R, Meenu Gill M et al. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate Prostate International 2014; 2; 21–30GuptaVGargMChaudhryMSinghSSenRMeenu GillMRole of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostateProstate International20142213010.12954/PI.14041409940025032195Search in Google Scholar

[8]Khoo ML, Beasley NJ, Ezzat S J, Freeman L and Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J. Clin. EndocrinolMetab 2002; 87: 1814–1818.KhooMLBeasleyNJEzzatS JFreemanLAsaSLOverexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinomaJ. Clin. EndocrinolMetab2002871814181810.1210/jcem.87.4.835311932323Search in Google Scholar

[9]Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, et al. DJ-1 binds androgen receptor directlyand mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67(10):4630–7.TillmanJEYuanJGuGFazliLGhoshRFlyntASDJ-1 binds androgen receptor directlyand mediates its activity in hormonally treated prostate cancer cellsCancer Res200767104630710.1158/0008-5472.CAN-06-455617510388Search in Google Scholar

[10]Mohammed AA. Biomarkers in prostate cancer: new era and prospective. Med Oncol. 2014; 31:140.MohammedAABiomarkers in prostate cancer: new era and prospectiveMed Oncol20143114010.1007/s12032-014-0140-325048724Search in Google Scholar

[11]Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, et al. Expression of cell cycle regulated genes and prostate cancer prognosis in a population-based cohort. Prostate. 2015 Sep; 75:1354–62.RubiczRZhaoSAprilCWrightJLKolbSColemanIExpression of cell cycle regulated genes and prostate cancer prognosis in a population-based cohortProstate2015Sep7513546210.1002/pros.23016Search in Google Scholar

[12]Knudsen K. E., Scher H. I. (2009) Clin. Cancer Res. 2009; 15, 4792–4798.KnudsenK. E.ScherH. I.2009Clin. Cancer Res.2009154792479810.1158/1078-0432.CCR-08-2660Search in Google Scholar

[13]Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000; 6:1891–1895.DrobnjakMOsmanIScherHIFazzariMCordon-CardoCOverexpression of cyclin D1 is associated with metastatic prostate cancer to boneClin Cancer Res2000618911895Search in Google Scholar

[14]Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology. 2011; 58:781–789.FleischmannARochaCSaxer-SekulicNZlobecISauterGThalmannGNHigh-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patientsHistopathology20115878178910.1111/j.1365-2559.2011.03800.xSearch in Google Scholar

[15]Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol. 2000; 53:15–18.KolarZMurrayPGScottKHarrisonAVojtesekBDusekJRelation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancerMol Pathol200053151810.1136/mp.53.1.15Search in Google Scholar

[16]Ueda N, Yamashita M, Kuroda I, Takenaka I. Immunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimens. Nishinihon J Urol 2001; 63:246–9.UedaNYamashitaMKurodaITakenakaIImmunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimensNishinihon J Urol2001632469Search in Google Scholar

[17]Qahtani FF, Atta IS, Mady EA. P63 and Cyclin D 1 Expression in Benign Prostatic Hyperplasia versus Prostatic Adenocarcinoma: A Clinicopathologic, Radiologic, and Immunohistochemical Study. International Journal of Healthcare Sciences 2015; 2: 320–305.QahtaniFFAttaISMadyEAP63 and Cyclin D 1 Expression in Benign Prostatic Hyperplasia versus Prostatic Adenocarcinoma: A Clinicopathologic, Radiologic, and Immunohistochemical StudyInternational Journal of Healthcare Sciences20152320305Search in Google Scholar

[18]Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6:1891–1895.DrobnjakMOsmanIScherHIFazzariMCordon-CardoCOverexpression of cyclin D1 is associated with metastatic prostate cancer to boneClin Cancer Res2000618911895Search in Google Scholar

[19]Kallakury B.V., Sheehan C.E., Ambros R.A., Kaufman H.A and Ross JS. The prognostic significance of p34 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997; 80: 753–763.KallakuryB.V.SheehanC.E.AmbrosR.A.KaufmanH.ARossJSThe prognostic significance of p34 and cyclin D1 protein expression in prostate adenocarcinomaCancer19978075376310.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-SSearch in Google Scholar

[20]Lev N, Roncevic D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson’s disease. J Mol Neurosci. 2006; 29:215–25. Review. Erratum in: J Mol Neurosci. 2007; 31:307.LevNRoncevicDIckowiczDMelamedEOffenDRole of DJ-1 in Parkinson’s diseaseJ Mol Neurosci20062921525Review. Erratum in: J Mol Neurosci. 2007; 31:307.10.1385/JMN:29:3:215Search in Google Scholar

[21]Ismail IA, Kang HS, Lee HJ, Kim JK, Hong SH. DJ.1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer. 2014 Mar 4; 110:1298–306.IsmailIAKangHSLeeHJKimJKHongSHDJ.1 upregulates breast cancer cell invasion by repressing KLF17 expressionBr J Cancer.2014Mar4110129830610.1038/bjc.2014.40Search in Google Scholar

[22]Lisitskaia KV, Eremina LS, Ivanov AV, Kovaleva MA, Okhrits V, Toropygin IIu, et al. Study of DJ-1 protein in tissuespecimens cultured cells and serum of prostate cancer patients. Biomed Khim 2011;57:392–401.LisitskaiaKVEreminaLSIvanovAVKovalevaMAOkhritsVToropyginIIuStudy of DJ-1 protein in tissuespecimens cultured cells and serum of prostate cancer patientsBiomed Khim20115739240110.18097/pbmc20115704392Search in Google Scholar

[23]Osman W, Attia R and Abou Gabal H. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesis. Egypt Natio Can Inst J 2013; 25:223–230.OsmanWAttiaRAbou GabalHDJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesisEgypt Natio Can Inst J20132522323010.1016/j.jnci.2013.08.001Search in Google Scholar

[24]Wang Q, Li F, Shi W, Zhang Q, Wang J, Yan X, et al. Overexpression of DJ-1 correlates with aggressive clinicopathological characteristics and poor prognosis in malignant tumors: a meta-analysis. Onco Targets Ther. 2018; 11:3931–3942.WangQLiFShiWZhangQWangJYanXOverexpression of DJ-1 correlates with aggressive clinicopathological characteristics and poor prognosis in malignant tumors: a meta-analysisOnco Targets Ther2018113931394210.2147/OTT.S162045Search in Google Scholar

[25]Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 2008; 7:1745–1762.LeeJTLehmannBDTerrianDMChappellWHStivalaFLibraMTargeting prostate cancer based on signal transduction and cell cycle pathwaysCell Cycle200871745176210.4161/cc.7.12.6166259347518594202Search in Google Scholar

[26]Comstock CE, Revelo MR, Bunche CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007; 96: 970–979.ComstockCEReveloMRBuncheCRKnudsenKEImpact of differential cyclin D1 expression and localisation in prostate cancerBr J Cancer20079697097910.1038/sj.bjc.6603615236009017375037Search in Google Scholar

[27]Ozbek E, Mizrak B, Ozbek M, Buyukberber S, Davarci M. Cyclin-D1 protooncogen expression in prostate cancer. Turk J Cancer 2000; 30: 15–21OzbekEMizrakBOzbekMBuyukberberSDavarciMCyclin-D1 protooncogen expression in prostate cancerTurk J Cancer2000301521Search in Google Scholar

[28]Shiraishi T, Watanabe M, Muneyuki T, Nakayama, Morita J, Ito H, et al. clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 1998; 61 p: 90–94ShiraishiTWatanabeMMuneyukiTNakayamaMoritaJItoHclinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancersUrol Int199861909410.1159/0000302959873247Search in Google Scholar

[29]Prahlad V. Raninga, Trapani G, Kathryn F. Cross talk between two antioxidant systems, Thioredoxin and DJ-1. Oncoscience 2014; 1 (1).RaningaPrahlad V.TrapaniGKathrynFCross talk between two antioxidant systems, Thioredoxin and DJ-1Oncoscience20141110.18632/oncoscience.12429576025593990Search in Google Scholar

[30]Imrali A, Mao X, Yester-Velasco M. Shamash J, Lu Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res 2016; 6:1772–1784.ImraliAMaoXYester-VelascoMShamashJLuYRapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatinAm J Cancer Res2016617721784Search in Google Scholar